Biodesix, Inc. (BDSX), a diagnostic solutions company continues to make strides in advancing its innovative lung cancer diagnostics.
The performance of the company's Nodify CDT blood-based test has been reaffirmed in a post-market clinical validation study published in the CHEST Pulmonary Journal.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com